Please login to the form below

Not currently logged in
Email:
Password:

Epclusa

This page shows the latest Epclusa news and features for those working in and with pharma, biotech and healthcare.

NHS England sees off AbbVie's Hep C legal challenge

NHS England sees off AbbVie's Hep C legal challenge

Maviret is in contention with rival treatments such as Gilead’s Sovaldi, Harvoni and Epclusa, to name a few.

Latest news

  • AbbVie sues NHS England over hep C procurement AbbVie sues NHS England over hep C procurement

    treatment – as well as follow-up combinations such as Harvoni (sofosbuvir/ledipasvir) as well as Epclusa (sofosbuvir/velpatasvir) that was effective against all HCV genotypes.

  • Merck & Co pulls out of hepatitis C R&D as market shrinks Merck & Co pulls out of hepatitis C R&D as market shrinks

    In the same period, Gilead’s HCV portfolio of Harvoni (sofosbuvir/ledipasvir), Epclusa (sofosbuvir/velpatasvir) and Sovaldi (sofosbuvir) brought in $5.44bn, down from around $8.3bn in the first half

  • Gilead gets OK for three-in-one hep C therapy in US Gilead gets OK for three-in-one hep C therapy in US

    The single-tablet triple therapy contains NS5B polymerase inhibitor sofosbuvir and NS5A inhibitor velpatasvir - the two active ingredients in Gilead's recently-approved two-drug HCV combination Epclusa - as well as ... Sovaldi and follow-ups Harvoni and

  • Two new hepatitis C therapies fast-tracked in Europe Two new hepatitis C therapies fast-tracked in Europe

    It is dosed once daily as three oral tablets and is being billed as a rival to Epclusa, which is dosed over 12 weeks in all patients. ... Analysts at Leerink have previously predicted that combined sales of Harvoni, Sovaldi and Epclusa will be $2.5bn a

  • Gilead files hepatitis C salvage regimen in US Gilead files hepatitis C salvage regimen in US

    The two other studies - POLARIS-2 and 3 - compared the triple combination regimen in treatment-naïve patients given for eight weeks to Epclusa given for 12 weeks. ... The SVR rates were comparable between the new regimen and Epclusa in both trials.

More from news
Approximately 8 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    In other news from Gilead, the company has created a new subsidiary, Asegua Therapeutics, which will launch authorised generic versions of Epclusa and Harvoni, Gilead’s treatments for hepatits C virus

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics